Pre-made Codrituzumab benchmark antibody ( Whole mAb, anti-GPC3 therapeutic antibody, Anti-DGSX/GTR2-2/MXR7/OCI-5/SDYS/SGB/SGBS/SGBS1 Antibody) for drug discovery and mechanism of action (MOA) research

Pre-Made Codrituzumab biosimilar, Whole mAb, Anti-GPC3 Antibody: Anti-DGSX/GTR2-2/MXR7/OCI-5/SDYS/SGB/SGBS/SGBS1 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Codrituzumab is a humanized monoclonal antibody targeted at glypican-3 (GPC3), which is a member of the glypican family. This drug is developed by Chugai Pharmaceutical in combination with Roche and has been investigated in the treatment of liver cancer.

Order information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No.	Package	Price(In USD)	Qty (Quantity)	Sum(In USD)
GMP-Bios-ab-114-1mg	1mg	3090
GMP-Bios-ab-114-10mg	10mg	Inquiry
GMP-Bios-ab-114-100mg	100mg	Inquiry
GMP-Bios-ab-114-xmg	≥100mg	Inquiry
			Shipping Cost:	760.00
			Total:

Description

Products Name (INN Index)	Pre-Made Codrituzumab biosimilar, Whole mAb, Anti-GPC3 Antibody: Anti-DGSX/GTR2-2/MXR7/OCI-5/SDYS/SGB/SGBS/SGBS1 therapeutic antibody
INN Name	Codrituzumab
Target	GPC3
Format	Whole mAb
Derivation	Humanized
Species Reactivity	Human
CH1 Isotype	IgG1
VD LC	Kappa
Highest_Clin_Trial (Jan '20)	Phase-II
Est. Status	Active
100% SI Structure	None
99% SI Structure	None
95-98% SI Structure	None
Year Proposed	2013
Year Recommended	2014
Companies	Perseus Proteomics;Chugai Pharmaceutical;Roche
Conditions Approved	na
Conditions Active	Liver cancer
Conditions Discontinued	na
Development Tech	na